The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team will present and host 1x1 meetings at the Stifel ...

Vaccine stocks have been under significant pressure in recent days following news that the FDA director who oversaw the ...

European shares declined on Wednesday, dragged down in particular by healthcare stocks, as investors awaited tariff plans ...

Economists at the Office for Budget Responsibility have warned that US tariffs could eliminate Reeves's "headroom" against her day-to-day spending plans, requiring her to make more cuts or hike taxes ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

The European Medicines Agency has temporarily suspended enrollment and dosing in a Phase II trial of Sarepta Therapeutics' ...

Nurix Therapeutics (NRIX) announced that Sanofi (SNY) has exclusively licensed an undisclosed Nurix program targeting a previously undruggable ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable transcription ...

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune ...